Quyen D Chu1, Meijiao Zhou2, Prakash Peddi3, Kaelen L Medeiros2, Gazi B Zibari4, Hosein Shokouh-Amiri4, Xiao-Cheng Wu2. 1. Department of Surgery, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA; The Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA. 2. Louisiana Tumor Registry & Epidemiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA; School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA. 3. Department of Medicine, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA; The Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA. Electronic address: ppeddi@lsuhsc.edu. 4. Department of Surgery, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA; John C McDonald Regional Transplant Center, Willis Knighton Health System, Shreveport, LA, USA.
Abstract
INTRODUCTION: Although a volume-outcome relationship has been well established for pancreatectomy, little is known about differences in mortality by facility type. The objective of this study is to evaluate the impact of facility type on short-term and long-term survival outcomes for patients with pancreatic adenocarcinoma who underwent pancreatectomy and identify determinants of overall survival (OS). METHODS: A cohort of 33,382 patients with Stage I-III pancreatic adenocarcinoma diagnosed between 1998 and 2011 were evaluated from the National Cancer Data Base. Clinicopathological, sociodemographic and treatment variables were compared among three facility types where patients received resection: (i) community cancer program (CCP), (ii) comprehensive community cancer program (CCCP), and (iii) academic research program (ARP). 5-year OS was calculated using the Kaplan-Meier method. RESULTS: Despite ARP having significantly higher percentage of poorly differentiated tumors, higher T-stage tumors, more positive lymph nodes, and greater circle distance compared to the other facilities, it had the highest 5-yr OS. The 5-yr OS for CCP, CCCP, and ARP was 11.2%, 13.2%, and 16.6%, respectively (P < 0.0001) and the median survival time (months) was 12.4, 15.6 and 19.1, respectively. CONCLUSION: Patients receiving pancreatic resection at an ARP yielded a higher 5-year OS compared to CCP or CCCP. Published by Elsevier Ltd.
INTRODUCTION: Although a volume-outcome relationship has been well established for pancreatectomy, little is known about differences in mortality by facility type. The objective of this study is to evaluate the impact of facility type on short-term and long-term survival outcomes for patients with pancreatic adenocarcinoma who underwent pancreatectomy and identify determinants of overall survival (OS). METHODS: A cohort of 33,382 patients with Stage I-III pancreatic adenocarcinoma diagnosed between 1998 and 2011 were evaluated from the National Cancer Data Base. Clinicopathological, sociodemographic and treatment variables were compared among three facility types where patients received resection: (i) community cancer program (CCP), (ii) comprehensive community cancer program (CCCP), and (iii) academic research program (ARP). 5-year OS was calculated using the Kaplan-Meier method. RESULTS: Despite ARP having significantly higher percentage of poorly differentiated tumors, higher T-stage tumors, more positive lymph nodes, and greater circle distance compared to the other facilities, it had the highest 5-yr OS. The 5-yr OS for CCP, CCCP, and ARP was 11.2%, 13.2%, and 16.6%, respectively (P < 0.0001) and the median survival time (months) was 12.4, 15.6 and 19.1, respectively. CONCLUSION:Patients receiving pancreatic resection at an ARP yielded a higher 5-year OS compared to CCP or CCCP. Published by Elsevier Ltd.
Authors: Grace C Lee; T Clark Gamblin; Zhi Ven Fong; Cristina R Ferrone; Lipika Goyal; Keith D Lillemoe; Lawrence S Blaszkowsky; Kenneth K Tanabe; Motaz Qadan Journal: Ann Surg Oncol Date: 2019-07-31 Impact factor: 5.344
Authors: Lu Wu; Diamantis I Tsilimigras; Anghela Z Paredes; Rittal Mehta; J Madison Hyer; Katiuscha Merath; Kota Sahara; Fabio Bagante; Eliza W Beal; Feng Shen; Timothy M Pawlik Journal: World J Surg Date: 2019-07 Impact factor: 3.352
Authors: Nadia N Khan; Tennille Lewin; Amy Hatton; Charles Pilgrim; Liane Ioannou; Luc Te Marvelde; John Zalcberg; Sue Evans Journal: Am J Cancer Res Date: 2022-02-15 Impact factor: 6.166
Authors: David A Barrington; Jennifer A Sinnott; Danaye Nixon; Tasleem J Padamsee; David E Cohn; Kemi M Doll; Macarius M Donneyong; Ashley S Felix Journal: Am J Obstet Gynecol Date: 2022-03-10 Impact factor: 10.693
Authors: Aman Opneja; Gino Cioffi; Asrar Alahmadi; Nelroy Jones; Tin-Yun Tang; Nirav Patil; David L Bajor; Joel N Saltzman; Amr Mohamed; Eva Selfridge; Ankit Mangla; Jill Barnholtz-Sloan; Richard T Lee Journal: Cancer Med Date: 2021-05-31 Impact factor: 4.711
Authors: Andrea N Riner; Patrick W Underwood; Kai Yang; Kelly M Herremans; Miles E Cameron; Srikar Chamala; Peihua Qiu; Thomas J George; Jennifer B Permuth; Nipun B Merchant; Jose G Trevino Journal: Cancer Med Date: 2020-04-13 Impact factor: 4.452